ERBB2 and breast cancer: Currently, T-DM1 is FDA approved for two indications, as a second-line treatment of HER2-positive metastatic BC and as an adjuvant treatment of HER2-positive early BC with residual invasive cancer after neoadjuvant treatment [6].